Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $22.9 million.

  • Exagen's Shares Outstanding (Weighted Average) rose 2566.69% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 2566.69%. This contributed to the annual value of $18.2 million for FY2024, which is 296.15% up from last year.
  • Per Exagen's latest filing, its Shares Outstanding (Weighted Average) stood at $22.9 million for Q3 2025, which was up 2566.69% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Shares Outstanding (Weighted Average) peaked at $22.9 million during Q3 2025, and registered a low of $12.9 million during Q1 2021.
  • Over the past 5 years, Exagen's median Shares Outstanding (Weighted Average) value was $17.7 million (recorded in 2023), while the average stood at $17.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 3401.71% in 2021, then soared by 76.74% in 2022.
  • Exagen's Shares Outstanding (Weighted Average) (Quarter) stood at $16.0 million in 2021, then increased by 6.95% to $17.1 million in 2022, then rose by 3.5% to $17.7 million in 2023, then rose by 2.96% to $18.2 million in 2024, then increased by 26.03% to $22.9 million in 2025.
  • Its last three reported values are $22.9 million in Q3 2025, $21.1 million for Q2 2025, and $18.6 million during Q1 2025.